From: ISO 10993 biological evaluation of novel hemostatic powder – 4SEAL®
Group | PT | APTT | HGB | HCT | platelets | RBC’s | WBC | Lymphocytes | Monocytes | Granulocytes |
---|---|---|---|---|---|---|---|---|---|---|
[sec.] | [sec.] | [g/dL] | [%] | [× 10 3/mm3] | [× 10 6/ mm3] | [× 10 3 /mm3] | [%] | [%] | [%] | |
Negative control – female | 9.05 | 17.83 | 13.42 | 30.28 | 783.20 | 7.39 | 6.72 | 59.80 | 17.54 | 22.66 |
4SEAL® - female | 7.80 | 20.08 | 12.80 | 29.30 | 752.40 | 7.23 | 5.40 | 53.50 | 17.36 | 29.02 |
Negative control – male | 10.16 | 17.88 | 13.68 | 31.12 | 778.60 | 7.36 | 7.58 | 54.02 | 16.58 | 29.42 |
4SEAL® - male | 11.28 | 22.08 | 13.16 | 30.16 | 748.80 | 7.39 | 6.14 | 55.24 | 17.88 | 26.88 |